HD12 randomised trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): An analysis of the german Hodgkin lymphoma study group (GHSG), University of Cologne, D-50924 Cologne, Germany.

被引：0
|
作者：
Engert, Andreas
Franklin, Jeremy
Mueller, Rolf-Peter
Eich, Hans-Theodor
Gossmann, Axel
Mueller-Hermelink, Hans Konrad
Cemy, Thomas
Markova, Jana
Ho, Anthony D.
Kanz, Lothar
Greil, Richard
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, Coordinat Ctr Clin Trials, Cologne, Germany
[3] Univ Hosp Cologne, Dept Radiotherapy, Cologne, Germany
[4] Univ Wurzburg, Inst Pathol, Wurzburg, Germany
[5] Dept Internal Med, St Gallen, Switzerland
[6] Prague Univ, Dept Hematol, Prague, Czech Republic
[7] Univ Heidelberg, Dept Hematol & Oncol, Heidelberg, Germany
[8] Univ Tubingen, Dept Internal Med, D-7400 Tubingen, Germany
[9] Salzburg Univ, Dept Internal Med 3, A-5020 Salzburg, Austria
[10] Univ Hosp Munich, Dept Internal Med 3, Munich, Germany
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页码：33A / 33A
页数：1
相关论文
共 26 条
  • [1] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG)
    Diehl, V.
    Haverkamp, H.
    Mueller, R.
    Mueller-Hermelink, H.
    Cerny, T.
    Markova, J.
    Ho, A. D.
    Kanz, L.
    Greil, R.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with our without radiotherapy in patients in advanced stage Hodgkin Lymphoma (HL): Final analysis of the randomised HD12 trial of the German Hodgkin Study Group (GHSG)
    Eich, H. T.
    Mueller, R-P.
    Haverkamp, H.
    Gossmann, A.
    Staar, S.
    Kriz, J.
    Lukas, P.
    Willich, N.
    Engenhart-Cabillic, R.
    Engert, A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 26 - 26
  • [3] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG)
    Diehl, Volker
    Haverkamp, Heinz
    Mueller, Rolf Peter
    Eich, Hans Theodor
    Mueller-Hermelink, Hans Konrad
    Cerny, Thomas
    Markova, Jana
    Ho, Anthony
    Kanz, Lothar
    Greil, Richard
    Hiddemann, Wolfgang
    Engert, Andreas
    BLOOD, 2008, 112 (11) : 552 - 553
  • [4] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced-stage Hodgkin Lymphoma (HL): Final Analysis of the Randomized HD12 Trial of the German Hodgkin Study Group (GHSG)
    Eich, H.
    Engert, A.
    Haverkamp, H.
    Staar, S.
    Kriz, J.
    Engenhart-Cabillic, R.
    Lukas, P.
    Willich, N.
    Diehl, V.
    Mueller, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S3 - S4
  • [5] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
    Borchmann, Peter
    Haverkamp, Heinz
    Diehl, Volker
    Cerny, Thomas
    Markova, Jana
    Ho, Anthony D.
    Eich, Hans-Theodor
    Mueller-Hermelink, Hans Konrad
    Kanz, Lothar
    Greil, Richard
    Rank, Andreas
    Paulus, Ursula
    Smardova, Lenka
    Huber, Christoph
    Doerken, Bernd
    Nerl, Christoph
    Krause, Stefan W.
    Mueller, Rolf-Peter
    Fuchs, Michael
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4234 - 4242
  • [6] Results of the third interim analysis of the HD12 trial of the GHSG: 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkin's lymphoma.
    Diehl, V
    Schiller, P
    Engert, A
    Wolf, J
    Josting, A
    Mueller, RP
    Eich, HT
    Gossmann, A
    Mueller-Hermelink, HK
    Franklin, J
    Cerny, T
    Markova, J
    Ho, AD
    Kanz, L
    Greil, R
    Hiddemann, W
    BLOOD, 2003, 102 (11) : 27A - 28A
  • [7] 10-year results of the HD9 trial of the German Hodgkin study group (GHSG) comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma
    Diehl, V.
    Franklin, J.
    Fuchs, M.
    Pfistner, B.
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
  • [8] Mortality during treatment of patients with advanced Hodgkin's lymphoma undergoing dose escalated BEACOPP chemotherapy: An analysis of the German Hodgkin study group (GHSG).
    Fuchs, M
    Franklin, J
    Klimm, B
    Josting, A
    Pfistner, B
    Engert, A
    Diehl, V
    BLOOD, 2005, 106 (11) : 749A - 749A
  • [9] 10-year results of the HD9 trial of the German Hodgkin study group comparing baseline and escalated BEACOPP chemotherapy for advanced hodgkin lymphoma
    Diehl, V.
    Franklin, J.
    Fuchs, M.
    Pfistner, B.
    Engert, A.
    ONKOLOGIE, 2008, 31 : 118 - 118
  • [10] 10-year results of the HD9 trial of the German Hodgkin study group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma
    Diehl, V.
    Franklin, J.
    Pfistner, B.
    Engert, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 69 - 70
123